Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?

Weir, R.A.P., Mark, P.B. , Petrie, C.J., Clements, S., Steedman, T., Ford, I. , Ng, L.L., Squire, I.B., Wagner, G.S. and McMurray, J.J.V. (2009) Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect? American Heart Journal, 157(6), pp. 1088-1096. (doi:10.1016/j.ahj.2009.04.001)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.ahj.2009.04.001

Abstract

Aims Aldosterone antagonism reduces cardiovascular morbidity and mortality in patients with left ventricular (LV) systolic dysfunction and heart failure or diabetes after acute myocardial infarction (AMI). The mechanism of this effect is unclear. We performed a contrast-enhanced cardiac magnetic resonance study to assess the effects of eplerenone on LV remodeling after AMI. Methods One hundred patients (mean age, 58.9 +/- 12 years; 77% male) with LV systolic dysfunction but without heart failure or diabetes were randomized to 24 weeks' double-blind treatment with eplerenone or placebo started 1 to 14 days after AMI. Contrast-enhanced cardiac magnetic resonance was performed, and plasma concentrations of matrix metalloproteinase-2 (MMP-2) and MMP-9 were measured before randomization and at 12 and 24 weeks. Results Baseline LV ejection fraction was, by chance, significantly higher in eplerenone than in placebo-treated patients. Eplerenone had no effect on the primary end point (change in LV end-systolic volume index); after covariate adjustment, the primary end point fell by 6.1 +/- 2.7 mL/m(2) with eplerenone compared to placebo (P = .027), and LV end-diastolic volume index fell by 7.5 +/- 3.4 mL/m(2) (P = .031); eplerenone did not significantly influence LV ejection fraction. Eplerenone, after covariate adjustment, significantly decreased MMP-2 and increased MMP-9 over 24 weeks relative to placebo. Conclusions In a population of patients with AMI with high uptake of contemporary antiremodeling therapy, eplerenone provides modest incremental protection against LV remodeling, only after covariate adjustment.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Dr Patrick and McMurray, Professor John and Ford, Professor Ian and Hopkins, Mrs Tracey
Authors: Weir, R.A.P., Mark, P.B., Petrie, C.J., Clements, S., Steedman, T., Ford, I., Ng, L.L., Squire, I.B., Wagner, G.S., and McMurray, J.J.V.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
?? 20206000 ??
Journal Name:American Heart Journal
ISSN:0002-8703

University Staff: Request a correction | Enlighten Editors: Update this record